{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:29:42Z","timestamp":1793320182052,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402851"],"award-info":[{"award-number":["81402851"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573281"],"award-info":[{"award-number":["81573281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20140957"],"award-info":[{"award-number":["BK20140957"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["2015ZD009"],"award-info":[{"award-number":["2015ZD009"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Top-notch Academic Programs Project of Jiangsu Higher Education Institutions","award":["TAPP-PPZY2015A070"],"award-info":[{"award-number":["TAPP-PPZY2015A070"]}]},{"name":"Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejmech.2017.03.062","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T11:33:01Z","timestamp":1490614381000},"page":"294-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":311,"special_numbering":"C","title":["Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease"],"prefix":"10.1016","volume":"132","author":[{"given":"Qi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.03.062_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1750-3639.2007.00120.x","article-title":"MicroRNAs (miRNAs) in neurodegenerative diseases","volume":"18","author":"Nelson","year":"2008","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejmech.2016.03.077","article-title":"Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer's disease","volume":"116","author":"Zhang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib3","series-title":"Alzheimer's Disease International","author":"Prince","year":"2016"},{"key":"10.1016\/j.ejmech.2017.03.062_bib4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0047-6374(01)00309-8","article-title":"Acetylcholinesterase in Alzheimer's disease","volume":"122","author":"Talesa","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.ejmech.2017.03.062_bib5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib6","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (\u03c4) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.03.062_bib7","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1021\/jm400970m","article-title":"Oxidative stress in Alzheimer's disease: are we connecting the dots?","volume":"57","author":"Rosini","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exnr.2000.7397","article-title":"On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis","volume":"163","author":"Bartus","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib9","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1016\/j.bmcl.2010.04.059","article-title":"Synthesis and binding ability of 1,2,3-triazole-based triterpenoid receptors for recognition of Hg(2+) ion","volume":"20","author":"Yu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.062_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-510X(02)00274-5","article-title":"The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease","volume":"203\u2013204","author":"Grantham","year":"2002","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0166-2236(98)01361-7","article-title":"Acetylcholine in mind: a neurotransmitter correlate of consciousness?","volume":"22","author":"Perry","year":"1999","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0306-4522(01)00613-3","article-title":"Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine","volume":"110","author":"Mesulam","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2017.03.062_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj2600625","article-title":"Comparison of butyrylcholinesterase and acetylcholinesterase","volume":"260","author":"Chatonnet","year":"1989","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2017.03.062_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0301-0082(99)00047-7","article-title":"The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study","volume":"60","author":"Mack","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1021\/jm9014845","article-title":"Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor","volume":"53","author":"Carolan","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/jpet.107.133330","article-title":"The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency","volume":"324","author":"Li","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2006.11.005","article-title":"A\u00a0medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India","volume":"378","author":"Manoharan","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2017.03.062_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/03007990152673800","article-title":"A\u00a0new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase","volume":"17","author":"Greig","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2017.03.062_bib19","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2174\/1871527313666141023141545","article-title":"Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus","volume":"13","author":"Mushtaq","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ejmech.2017.03.062_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0197-0186(92)90189-X","article-title":"Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development\u2013a study of molecular forms","volume":"21","author":"Arendt","year":"1992","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2017.03.062_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(84)90116-8","article-title":"Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease","volume":"1","author":"Arendt","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2017.03.062_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0022-3565(24)39312-7","article-title":"Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase","volume":"293","author":"Xie","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1476-5381.1993.tb13486.x","article-title":"Degradation of acetylcholine in human airways: role of butyrylcholinesterase","volume":"108","author":"Norel","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/nbdi.2001.0462","article-title":"Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain","volume":"9","author":"Mesulam","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2017.03.062_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ardp.201300051","article-title":"Resveratrol derived butyrylcholinesterase inhibitors","volume":"346","author":"Csuk","year":"2013","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2017.03.062_bib26","doi-asserted-by":"crossref","first-page":"41141","DOI":"10.1074\/jbc.M210241200","article-title":"Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products","volume":"278","author":"Nicolet","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib27","doi-asserted-by":"crossref","first-page":"17640","DOI":"10.1016\/S0021-9258(19)37091-7","article-title":"Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding","volume":"267","author":"Shafferman","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib28","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1021\/jm501195e","article-title":"Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor","volume":"57","author":"Brus","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev.pa.34.040194.001433","article-title":"The cholinesterases: from genes to proteins","volume":"34","author":"Taylor","year":"1994","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2044.1997.084-az0080.x","article-title":"Cholinesterase. Its significance in anaesthetic practice","volume":"52","author":"Davis","year":"1997","journal-title":"Anaesthesia"},{"key":"10.1016\/j.ejmech.2017.03.062_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02750872","article-title":"Serum cholinesterase and histopathology of the liver in severe protein calorie malnutrition","volume":"39","author":"Dabke","year":"1972","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.ejmech.2017.03.062_bib32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/00207450600920910","article-title":"Acetylcholinesterase activity changes on visceral organs of VMH lesion-induced obese rats","volume":"116","author":"Paes","year":"2006","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib33","first-page":"43","article-title":"Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes","volume":"40","author":"Cucuianu","year":"2002","journal-title":"Rom. J. Intern. Med."},{"key":"10.1016\/j.ejmech.2017.03.062_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/jcla.1860080411","article-title":"Serum pseudocholinesterase and very-low-density lipoprotein metabolism","volume":"8","author":"Kutty","year":"1994","journal-title":"J.\u00a0Clin. Lab. Anal."},{"key":"10.1016\/j.ejmech.2017.03.062_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S1665-2681(19)30932-9","article-title":"Association between butyrylcholinesterase activity and low-grade systemic inflammation","volume":"11","author":"Lampon","year":"2012","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1665-2681(19)30940-8","article-title":"Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation","volume":"11","author":"Das","year":"2012","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0046-8177(84)80052-0","article-title":"Laboratory assessment of nutritional status","volume":"15","author":"Burritt","year":"1984","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib38","first-page":"158","article-title":"Protein-energy malnutrition: its effects on 4 metabolic parameters","volume":"10","author":"Camarero Gonzalez","year":"1995","journal-title":"Nutr. Hosp."},{"key":"10.1016\/j.ejmech.2017.03.062_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/adc.38.200.343","article-title":"The relation of oedema to serum protein and pseudocholinesterase levels in the malnourished infant","volume":"38","author":"Montgomery","year":"1963","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejmech.2017.03.062_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pathophys.2006.01.002","article-title":"Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests","volume":"13","author":"Ogunkeye","year":"2006","journal-title":"Pathophysiology"},{"key":"10.1016\/j.ejmech.2017.03.062_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0261-5614(89)90075-7","article-title":"Predictability of deterioration in marginally malnourished cancer patients during hospitalization","volume":"8","author":"Ravera","year":"1989","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejmech.2017.03.062_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0973-1482.39601","article-title":"Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy","volume":"4","author":"Chougule","year":"2008","journal-title":"J.\u00a0Cancer Res. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.nut.2005.06.011","article-title":"Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition","volume":"22","author":"Santarpia","year":"2006","journal-title":"Nutrition"},{"key":"10.1016\/j.ejmech.2017.03.062_bib44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.clinbiochem.2005.04.008","article-title":"Relationship between serum butyrylcholinesterase and the metabolic syndrome","volume":"38","author":"Randell","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1373\/clinchem.2005.059857","article-title":"Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem","volume":"52","author":"Calderon-Margalit","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF01851188","article-title":"The prognostic value of serum acetylcholinesterase in myocardial infarction. Theoretical and clinical considerations","volume":"181","author":"Menache","year":"1982","journal-title":"Res. Exp. Med."},{"key":"10.1016\/j.ejmech.2017.03.062_bib47","first-page":"71","article-title":"Serum pseudocholinesterase activity during experimental fattening","volume":"14","author":"Popescu","year":"1976","journal-title":"Med. Interne"},{"key":"10.1016\/j.ejmech.2017.03.062_bib48","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/BF01989883","article-title":"Pseudocholinesterase in obesity: hypercaloric diet induced changes in experimental obese mice","volume":"37","author":"Kutty","year":"1981","journal-title":"Experientia"},{"key":"10.1016\/j.ejmech.2017.03.062_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/cs0850077","article-title":"Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus","volume":"85","author":"Abbott","year":"1993","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib50","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1373\/clinchem.2005.065052","article-title":"Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity","volume":"52","author":"Valle","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/CCLM.2005.048","article-title":"Butyrylcholinesterase activity and metabolic syndrome in obese patients","volume":"43","author":"Alcantara","year":"2005","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ejmech.2017.03.062_bib52","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00405003","article-title":"Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats","volume":"34","author":"Annapurna","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2017.03.062_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/cs1010029","article-title":"Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?","volume":"101","author":"Rustemeijer","year":"2001","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0009-8981(78)90103-1","article-title":"Similar behaviour of lecithin:cholesterol acyltransferase and pseudocholinesterase in liver disease and hyperlipoproteinemia","volume":"85","author":"Cucuianu","year":"1978","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2017.03.062_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00004836-198610000-00025","article-title":"Serum cholinesterase in patients with fatty liver","volume":"8","author":"Nomura","year":"1986","journal-title":"J.\u00a0Clin. Gastroenterol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib56","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0024-3205(77)90448-9","article-title":"Hydrolysis of cocaine in human plasma by cholinesterase","volume":"20","author":"Stewart","year":"1977","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib57","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/taap.1997.8188","article-title":"Therapeutic use of butyrylcholinesterase for cocaine intoxication","volume":"145","author":"Mattes","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib58","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.7164\/antibiotics.46.1315","article-title":"Cyclophostin, acetylcholinesterase inhibitor from Streptomyces lavendulae","volume":"46","author":"Kurokawa","year":"1993","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.ejmech.2017.03.062_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.11.011","article-title":"Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses","volume":"148","author":"Lockridge","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cbi.2008.04.042","article-title":"The cholinesterases: analysis by pharmacogenomics in man","volume":"175","author":"Valle","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2017.03.062_bib61","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/jm8002075","article-title":"Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase","volume":"51","author":"Darvesh","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib62","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1021\/acs.jmedchem.5b01674","article-title":"Discovery of highly selective and nanomolar carbamate-based butyrylcholinesterase inhibitors by rational investigation into their inhibition mode","volume":"59","author":"Sawatzky","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib63","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/ml3001825","article-title":"Neuroprotective Tri- and Tetracyclic BChE Inhibitors releasing reversible inhibitors upon carbamate transfer","volume":"3","author":"Darras","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.062_bib64","first-page":"125","article-title":"Present state and future development of the therapy of Alzheimer disease","volume":"2","author":"Pomponi","year":"1990","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2017.03.062_bib65","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1021\/jm010080x","article-title":"Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure\/activity relationships for acetyl- and butyrylcholinesterase inhibitory action","volume":"44","author":"Yu","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib66","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.03.062_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1034\/j.1600-0404.2000.00311.x","article-title":"The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics","volume":"176","author":"Greig","year":"2000","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.ejmech.2017.03.062_bib68","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.bmcl.2010.01.035","article-title":"Design, synthesis and evaluation of carbamate-modified (-)-N(1)-phenethylnorphysostigmine derivatives as selective butyrylcholinesterase inhibitors","volume":"20","author":"Takahashi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.062_bib69","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1021\/jm049309+","article-title":"Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine","volume":"48","author":"Luo","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib70","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1021\/jm00101a011","article-title":"Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes","volume":"35","author":"de Costa","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2006-957926","article-title":"Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa","volume":"62","author":"Park","year":"1996","journal-title":"Planta Medica"},{"key":"10.1016\/j.ejmech.2017.03.062_bib72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejmech.2004.12.003","article-title":"Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine","volume":"40","author":"Decker","year":"2005","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib73","doi-asserted-by":"crossref","first-page":"21937","DOI":"10.1074\/jbc.274.31.21937","article-title":"Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid","volume":"274","author":"Chyan","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib74","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1021\/jm301411g","article-title":"Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease","volume":"55","author":"Yanovsky","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib75","first-page":"1616","article-title":"Cholinesterases inhibition by novel cis- and trans-3-arylaminocyclohexyl N,N-Dimethylcarbamates: biological evaluation and molecular modeling","volume":"27","author":"Yamazaki","year":"2016","journal-title":"J.\u00a0Braz. Chem. Soc."},{"key":"10.1016\/j.ejmech.2017.03.062_bib76","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/tx050014o","article-title":"Ortho effects for inhibition mechanisms of butyrylcholinesterase by o-substituted phenyl N-butyl carbamates and comparison with acetylcholinesterase, cholesterol esterase, and lipase","volume":"18","author":"Lin","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib77","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1021\/jm060682m","article-title":"Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase","volume":"49","author":"Decker","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acs.jmedchem.5b01119","article-title":"Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray crystallography","volume":"59","author":"Zha","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmech.2015.03.040","article-title":"Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease","volume":"95","author":"Xie","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib80","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1039\/C3OB42010H","article-title":"Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease","volume":"12","author":"Li","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib81","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0968-0896(98)00213-2","article-title":"Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis","volume":"7","author":"Carlier","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib82","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0960-894X(01)00294-3","article-title":"Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase","volume":"11","author":"Savini","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.062_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm0255668","article-title":"Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors","volume":"46","author":"Savini","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib84","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ardp.201300074","article-title":"Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease","volume":"346","author":"Chen","year":"2013","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2017.03.062_bib85","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.bmc.2013.03.005","article-title":"Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents","volume":"21","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib86","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.med.48.1.489","article-title":"Nitric oxide synthase: role in the genesis of vascular disease","volume":"48","author":"Cooke","year":"1997","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2017.03.062_bib87","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/cbdd.12800","article-title":"Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease","volume":"88","author":"Osman","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2017.03.062_bib88","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pbb.2012.09.018","article-title":"Tianeptine exerts neuroprotective effects in the brain tissue of rats exposed to the chronic stress model","volume":"103","author":"Della","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2017.03.062_bib89","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.mehy.2006.09.040","article-title":"Is hippocampal atrophy a future drug target?","volume":"68","author":"Dhikav","year":"2007","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejmech.2017.03.062_bib90","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejmech.2017.03.062_bib91","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ejmech.2016.06.025","article-title":"Novel series of tacrine-tianeptine hybrids: synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach","volume":"121","author":"Ceschi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib92","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.bmc.2014.08.035","article-title":"Design, synthesis and evaluation of novel tacrine-(beta-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease","volume":"22","author":"Lan","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0378-8741(87)90005-5","volume":"19","author":"Cyong","year":"1987","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib94","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.oraloncology.2008.07.012","article-title":"Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in\u00a0vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor","volume":"45","author":"Lin","year":"2009","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib95","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0960-894X(00)00645-4","article-title":"3-p-Toluoyl-2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran and 2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran do not act as surfactants or micelles when inhibiting the aggregation of beta-amyloid peptide","volume":"11","author":"Allsop","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.062_bib96","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ejmech.2012.10.045","article-title":"2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents","volume":"58","author":"Rizzo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib97","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/jm201460y","article-title":"New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties","volume":"55","author":"Fernandez-Bachiller","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/157488911795933938","article-title":"BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity","volume":"6","author":"Evin","year":"2011","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.ejmech.2017.03.062_bib99","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/molecules18022397","article-title":"7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment\u2013synthesis, biological evaluation and molecular modeling studies","volume":"18","author":"Spilovska","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2017.03.062_bib100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","article-title":"Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study","volume":"206","author":"Kornhuber","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib101","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.20968","article-title":"Association between amantadine and the onset of dementia in Parkinson's disease","volume":"21","author":"Inzelberg","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2017.03.062_bib102","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2165\/00003495-200666110-00015","article-title":"Memantine: a review of its use in Alzheimer's disease","volume":"66","author":"Robinson","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2017.03.062_bib103","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/ern.12.124","article-title":"Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease","volume":"12","author":"Francis","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2017.03.062_bib104","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.febslet.2009.06.042","article-title":"Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models","volume":"583","author":"Yamashita","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2017.03.062_bib105","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1023\/B:BEBM.0000017097.75818.14","article-title":"Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons","volume":"136","author":"Grigorev","year":"2003","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2017.03.062_bib106","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","article-title":"Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer","volume":"939","author":"Bachurin","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib107","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/jpet.109.164491","article-title":"Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism","volume":"333","author":"Giorgetti","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib108","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/cmdc.201300263","article-title":"The bivalent ligand approach as a tool for improving the in\u00a0vitro anti-Alzheimer multitarget profile of dimebon","volume":"8","author":"Rosini","year":"2013","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib109","doi-asserted-by":"crossref","first-page":"13164","DOI":"10.1038\/srep13164","article-title":"Conjugates of gamma-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer disease","volume":"5","author":"Makhaeva","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2017.03.062_bib110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejmech.2016.09.037","article-title":"New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity","volume":"125","author":"de Candia","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib111","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1021\/jm401047q","article-title":"Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen","volume":"56","author":"Luo","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib112","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib113","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pnpbp.2013.02.001","article-title":"An update on amine oxidase inhibitors: multifaceted drugs","volume":"44","author":"Song","year":"2013","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2017.03.062_bib114","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejmech.2015.10.001","article-title":"Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological evaluation","volume":"121","author":"Wu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib115","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.bmc.2016.07.025","article-title":"Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin","volume":"24","author":"Wang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib116","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1021\/cn500081s","article-title":"Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin","volume":"5","author":"Chojnacki","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2017.03.062_bib117","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/DDDT.S49763","article-title":"8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications","volume":"7","author":"Prachayasittikul","year":"2013","journal-title":"Drug Des. devel. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib118","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.4155\/fmc.15.79","article-title":"Rational approach to an antiprion compound with a multiple mechanism of action","volume":"7","author":"Bolognesi","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib119","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1021\/jm100329q","article-title":"Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties","volume":"53","author":"Fernandez-Bachiller","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","article-title":"Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta","volume":"59","author":"Adlard","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2017.03.062_bib121","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF03401927","article-title":"L.\u00a0B. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy","volume":"4","author":"Arbiser","year":"1998","journal-title":"Chen, Mol. Med."},{"key":"10.1016\/j.ejmech.2017.03.062_bib122","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/cmdc.201600014","article-title":"Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer's disease","volume":"11","author":"Prati","year":"2016","journal-title":"Chem. Med .Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib123","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1755-5949.2010.00147.x","article-title":"REVIEW: curcumin and Alzheimer's disease","volume":"16","author":"Hamaguchi","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejmech.2017.03.062_bib124","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.L110.133520","article-title":"Curcumin and Alzheimer disease: this marriage is not to be performed","volume":"286","author":"Mancuso","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.brainresrev.2006.04.004","article-title":"Resveratrol\u2013a boon for treating Alzheimer's disease?","volume":"52","author":"Anekonda","year":"2006","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ejmech.2017.03.062_bib126","doi-asserted-by":"crossref","first-page":"37377","DOI":"10.1074\/jbc.M508246200","article-title":"Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides","volume":"280","author":"Marambaud","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib127","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2165\/00003088-199631040-00002","article-title":"Clinical pharmacokinetics of bambuterol","volume":"31","author":"Sitar","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2017.03.062_bib128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0090-9556(25)07050-3","article-title":"Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood","volume":"16","author":"Tunek","year":"1988","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.03.062_bib129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1124\/dmd.114.060251","article-title":"Stereoselective inhibition of human butyrylcholinesterase by the enantiomers of bambuterol and their intermediates","volume":"43","author":"Pistolozzi","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.03.062_bib130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/BF01898049","article-title":"2 new groups of selective stimulants of adrenergic beta-receptors","volume":"25","author":"Bergman","year":"1969","journal-title":"Experientia"},{"key":"10.1016\/j.ejmech.2017.03.062_bib131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1600-0773.1990.tb00733.x","article-title":"An analysis of the beta 2-adrenoceptor selectivity in three series of beta-adrenoceptor agonists","volume":"66","author":"Johansson","year":"1990","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2017.03.062_bib132","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejmech.2016.08.061","article-title":"Design, synthesis and biological evaluation of bambuterol analogues as novel inhibitors of butyrylcholinesterase","volume":"126","author":"Wu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib133","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cbi.2008.04.050","article-title":"Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers","volume":"175","author":"Bosak","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2017.03.062_bib134","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/1573406410666140526145429","article-title":"Quinoxaline derivatives: novel and selective butyrylcholinesterase inhibitors","volume":"10","author":"Zeb","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/1521-4184(200211)335:8<389::AID-ARDP389>3.0.CO;2-X","article-title":"Synthesis and antibacterial activity of fused 1, 2, 4-triazolo[4, 3-a]quinoxaline and oxopyrimido[2', 1':5, 1]-1, 2, 4-triazolo[4, 3-a]quinoxaline derivatives","volume":"335","author":"Nasr","year":"2002","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2017.03.062_bib136","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1016\/j.bmc.2006.04.029","article-title":"Design, synthesis, and biological evaluation of 1,2,3-trisubstituted-1,4-dihydrobenzo[g]quinoxaline-5,10-diones and related compounds as antifungal and antibacterial agents","volume":"14","author":"Tandon","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib137","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.trsl.2016.03.014","article-title":"Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target","volume":"175","author":"Singh","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2017.03.062_bib138","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1248\/cpb.c14-00158","article-title":"Molecular modeling studies and synthesis of novel methyl 2-(2-(4-oxo-3-aryl-3,4-dihydroquinazolin-2-ylthio)acetamido)alkanoates with potential anti-cancer activity as inhibitors for methionine synthase","volume":"62","author":"Elfekki","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2017.03.062_bib139","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-827X(99)00010-5","article-title":"Synthesis of 3,6,7-substituted-quinoxalin-2-ones for evaluation of antimicrobial and anticancer activity. Part 2","volume":"54","author":"Sanna","year":"1999","journal-title":"Farmaco"},{"key":"10.1016\/j.ejmech.2017.03.062_bib140","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1021\/jm00022a014","article-title":"Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides .2","volume":"38","author":"Monge","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib141","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem-Biol. Interact."},{"key":"10.1016\/j.ejmech.2017.03.062_bib142","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/092986706776360969","article-title":"Carboxylesterases - ddetoxifying enzymes and targets for drug therapy","volume":"13","author":"Potter","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib143","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.bmc.2016.01.031","article-title":"Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors","volume":"24","author":"Makhaeva","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib144","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1002\/chem.200601446","article-title":"Novel structural motifs consisting of chiral thiazolines: synthesis, molecular recognition, and anticancer activity","volume":"13","author":"Han","year":"2007","journal-title":"Chem-Eur. J."},{"key":"10.1016\/j.ejmech.2017.03.062_bib145","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/cr800189z","article-title":"Overview of the chemistry of 2-thiazolines","volume":"109","author":"Gaumont","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2017.03.062_bib146","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.bmc.2015.06.010","article-title":"Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents","volume":"23","author":"Knez","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib147","doi-asserted-by":"crossref","first-page":"7683","DOI":"10.1021\/acs.jmedchem.6b00356","article-title":"Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening","volume":"59","author":"Dighe","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib148","doi-asserted-by":"crossref","first-page":"10282","DOI":"10.1021\/jm300871x","article-title":"Structures of human acetylcholinesterase in complex with pharmacologically important ligands","volume":"55","author":"Cheung","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.062_bib149","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cbi.2010.01.042","article-title":"Acetylcholinesterase: from 3D structure to function","volume":"187","author":"Dvir","year":"2010","journal-title":"Chem. Boil. Interact."},{"key":"10.1016\/j.ejmech.2017.03.062_bib150","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/j.1742-4658.2012.08672.x","article-title":"Human butyrylcholinesterase produced in insect cells: huprine-based affinity purification and crystal structure","volume":"279","author":"Brazzolotto","year":"2012","journal-title":"FEBS J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417302283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417302283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:57:50Z","timestamp":1750168670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417302283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":150,"alternative-id":["S0223523417302283"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.062","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}